Published • loading... • Updated
CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update
Revenue rose 3% to $9.7 million as distributor and strategic partner sales increased 18%, helping the company reach operating cash flow breakeven.
- On Thursday, November 12, 2026, CytoSorbents Corporation reported third-quarter revenue of $9.7 million, up 3% year-over-year, and achieved positive operating cash flow of approximately $43,000, excluding restructuring payments.
- Efficiency gains drove these improvements, as the company reduced headcount by 24% since September 2025 and optimized manufacturing. Operating expenses fell 11% year-over-year to $8.5 million while product gross margins expanded to 75%.
- Distributor and strategic partner sales grew 18% year-over-year, representing 76% of quarterly revenue. To revitalize Germany, the company hired Alex Tiefenbacher as Senior Vice President of Direct Sales, planning additional hires through early 2027.
- CEO Dr. Phillip Chan announced a planned De Novo regulatory submission for DrugSorb-ATR in early 2027. The submission will include data from approximately 250 patients to strengthen the benefit-risk analysis required by FDA.
- Regarding future priorities, CytoSorbents aims to satisfy Nasdaq listing requirements by year-end 2026. Management is evaluating strategic alternatives for HemoDefend-BGA, seeking to monetize the universal blood filtration technology without substantial internal investment.
Insights by Ground AI
23 Articles
23 Articles
Coverage Details
Total News Sources23
Leaning Left3Leaning Right5Center12Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
15%
C 60%
R 25%
Factuality
To view factuality data please Upgrade to Premium
